A Clinical Study to Assess the Effectiveness of ENO Lime in Participants With Ajeerna Vyadhi (Acidity, Acid Indigestion, Indigestion, and Associated Nausea)
NCT ID: NCT07140341
Last Updated: 2025-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
40 participants
INTERVENTIONAL
2025-08-20
2025-09-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Speed of Action of a Product to Control Gastric Hydration and Gastroesophageal Reflux
NCT05060744
Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances
NCT02277886
Evaluation of the Efficacy and Safety of Eolo in Patients With NERD
NCT07041060
Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease
NCT01338077
Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum
NCT05129670
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ENO Lime
Participants will be instructed to take 1 sachet of ENO Lime powder with approximately 150 milliliters (ml) of normal water as a single dose. Participants will be advised to repeat the dose after 2-hours, if necessary (Maximum 2 sachet per 24-hours). Participants will be followed up for 24-hours.
ENO Lime
A fruit salt (sachet of 5-gram powder) with lime flavor containing Svarjiksara (Shudh) 2220 milligram (mg) and Nimbu Rasa (Citrus limon, Fruit Juice Powder) 150 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ENO Lime
A fruit salt (sachet of 5-gram powder) with lime flavor containing Svarjiksara (Shudh) 2220 milligram (mg) and Nimbu Rasa (Citrus limon, Fruit Juice Powder) 150 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants newly experiencing symptom/s of Ajeerna vyadhi for not more than 10 days.
* Participants with at least one symptom of Ajeerna vyadhi (according to Charak Samhita and Madhav Nidan) that is acidity (heartburn), acid indigestion (epigastric pain), indigestion (abdominal discomfort), or associated nausea.
* Participants with VAS score greater than or equal to (\>=) 40-mm and less than or equal to (\<=) 80-mm Ajeerna vyadhi (acidity, acid indigestion, indigestion, or associated nausea) at the Baseline visit.
* Participants are able to read, understand, and provide written informed consent.
* Participants who can understand and complete the VAS.
Exclusion Criteria
* Participants with Updrava of Ajeerna vyadhi (Complications of indigestion).
* Pregnant women (self-reported) and breastfeeding females or females intending to become pregnant during the study.
* Participant had surgery in the last 14 days.
* Participant has been exposed to barium meal 3 days before screening.
* Participants already on any indigestion or acidity medication.
* Participants taking any medicinal/over-the-counter (OTC)/ herbal medicine from the past 3 days.
* Participants on medications that could interact with ENO Lime (example, antacids, proton pump inhibitors, or H2 blockers) as per the judgment of the Investigator/designee.
* Participants with known hypersensitivity to any of the components of ENO Lime (Svarjiksara \[Shudh\], Nimbu Rasa \[Citrus limon, Fruit Juice Powder\]).
* Participants with a history of gastrointestinal (GI) disorders such as peptic ulcers, gastritis, irritable bowel syndrome (IBS), or other serious GI diseases.
* Participants with serious renal, hepatic, or cardiovascular diseases.
* Participants on a sodium restricted diet example, those suffering from hypertension or congestive heart failure.
* Participants who have participated in another clinical trial within the last 30 days.
* Any participant who, in the opinion of the investigator, should not participate in the study.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HALEON
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lifepoint Hospital
Pune, Maharashtra, India
Ojas Hospital
Pune, Maharashtra, India
Shri Krishna Super Speciality Institute of Ayurveda
New Delhi, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
300269
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.